Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma
This study is currently recruiting participants.
This study evaluates the safety and tolerability of the addition of immunostimulatory therapy consisting of focal radiation with or without the Toll-like receptor (TLR) agonist Poly ICLC in patients with cutaneous T-cell lymphoma (CTCL) receiving concurrent therapy with the histone deacetylase inhibitor (HDACI) Romidepsin.
Study Type: Interventional
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Pilot Study of a Novel Multimodality Immuno-Chemotherapy Platform for Patients With Advanced Cutaneous T Cell Lymphoma
Condition: Cutaneous T-cell Lymphoma
Drug: Poly ICLC
Radiation: Focal lesional radiation
Phase: Phase 1
External Link: https://clinicaltrials.gov/ct2/show/NCT02061449